Hungary approves China's CanSino vaccine for emergency use

By IANS | Published: March 24, 2021 02:41 AM2021-03-24T02:41:22+5:302021-03-24T05:31:13+5:30

Budapest, March 24 Hungary has granted China's CanSino vaccine emergency use authorisation, making it the second China-developed Covid-19 ...

Hungary approves China's CanSino vaccine for emergency use | Hungary approves China's CanSino vaccine for emergency use

Hungary approves China's CanSino vaccine for emergency use

Budapest, March 24 Hungary has granted China's CanSino vaccine emergency use authorisation, making it the second China-developed Covid-19 vaccine approved in the European country, Hungarian Chief Medical Officer Cecilia Muller said.

Apart from the CanSino vaccine, the National Institute of Pharmacy and Nutrition has also approved the import of CoviShield, the Indian version of the AstraZeneca vaccine, Muller told a news conference, Xinhua news agency reported on Tuesday.

"We will search the four corners of the world to have enough vaccines in the country," she said.

The Hungarian government has been enriching its inoculation program with multiple vaccines in the fight against a third wave of the pandemic. So far, it has gained access to vaccines from five producers worldwide, including China's Sinopharm.

The use of Russian and Chinese vaccines has greatly contributed to the acceleration of the Hungarian vaccine program, according to Hungarian Minister of Foreign Affairs and Trade Peter Szijjarto.

"Vaccine is not a question of ideology for us; it is a matter of saving lives. And if we had not contracted Chinese and Russian vaccines, we could not have saved the health and lives of so many Hungar," the minister said in a recent interview with Russia Today.

Hungary, the first European Union member state to purchase a Chinese vaccine and authorize its use, started to administer the Sinopharm vaccine on February 24.

( With inputs from IANS )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in app